(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone
Opiate Dependence
Explore 12 assets in Opiate Dependence →Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Jacques E. Chelly
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07211399CT.gov Transition From Acute to Chronic Opioid Use and Chronic Pain | — | Not Yet Recruiting | — | — | — |
NCT04177706CT.gov Ketamine for the Treatment of Opioid Use Disorder and Depression | — | Completed | — | — | — |
NCT04220489CT.gov Perioperative Ketamine in Opioid-Tolerant Patients Undergoing Lumbar Spine Surgery | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Opiate Dependence
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone (this asset) | Jacques E. Chelly | P2 | BB · 64 |
| Buprenorphine | Erin Winstanley | P4 | BBB |
| 17-ALLYL-4,5A-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE | University of California, San Francisco | P4 | BB |
| Lidocaine | University Medical Centre Ljubljana | P4 | BB |
| Marcaine | Denver Health and Hospital Authority | P4 | BB |
| Gabapentin | Brigham and Women's Hospital | P4 | BB |
| Epclusa | Saskatchewan Health Authority - Regina Area | P4 | BB |
| Genvoya | Saskatchewan Health Authority - Regina Area | P4 | BB |
| Sufentanyl | West Virginia University | P4 | BB |
+20 more in the Opiate Dependence cohort
Other indications for (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Pain Syndrome | — | P4 | BBB · 74 |
| Post-Traumatic Stress Disorder | — | P4 | BBB · 74 |
| Depressive Disorder | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone in Opiate Dependence. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/2-o-chlorophenyl-2-methylaminocyclohexanone-opiate-dependence
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →